Compared to neutrophil chemoattractants, relatively little is known about the mechanism neutrophils use to respond to chemorepellents. We previously found that the soluble extracellular protein dipeptidyl peptidase IV (DPPIV) is a neutrophil chemorepellent. In this report, we show that an inhibitor of the protease activated receptor 2 (PAR2) blocks DPPIV-induced human neutrophil chemorepulsion, and that PAR2 agonists such as trypsin, tryptase, 2f-LIGRL, SLIGKV, and AC55541 induce human neutrophil chemorepulsion. Several PAR2 agonists in turn block the ability of the chemoattractant fMLP to attract neutrophils. Compared to neutrophils from male and female C57BL/6 mice, neutrophils from male and female mice lacking PAR2 are insensitive to the chemorepulsive effects of DPPIV or PAR2 agonists. Acute respiratory distress syndrome (ARDS) involves an insult-mediated influx of neutrophils into the lungs. In a mouse model of ARDS, aspiration of PAR2 agonists starting 24 h after an insult reduce neutrophil numbers in the bronchoalveolar lavage (BAL) fluid, as well as the post-BAL lung tissue. Together, these results indicate that the PAR2 receptor mediates DPPIV-induced chemorepulsion, and that PAR2 agonists might be useful to induce neutrophil chemorepulsion.
INTRODUCTION
A variety of cell types exhibit chemotaxis toward chemoattractants, such as the movement of neutrophils toward the peptide fMLP. 1 Studies in both Dictyostelium discoideum and neutrophils have elucidated many aspects of chemotaxis mechanisms. 2 Comparatively, much less is known about the mechanisms used by cells to move away from chemorepellents. 3, 4 Based on initial studies on a Dictyostelium chemorepellent, [5] [6] [7] [8] [9] we found that the human extracellular protein dipeptidyl peptidase IV (DPPIV) is a chemorepellent for human and mouse neutrophils. 6, 10, 11 Since chemoattractants activate cell surface receptors, 4, 12, 13 an intriguing possibility is that a neutrophil Abbreviations: ARDS, acute respiratory distress syndrome; BAL, bronchoalveolar lavage; DPPIV, dipeptidyl peptidase IV; FMI, forward migration index; fMLP, N-formylmethionine-leucyl-phenylalanine; PAR, protease activated receptor; PAR1, protease activated receptor 1; PAR2, protease activated receptor 2; SEM, Standard error of the mean; TLCK, tosyl-L-lysyl-chloromethane hydrochloride; TNF-, Tumor necrosis factorchemorepellent such as DPPIV may also activate a neutrophil cellsurface receptor.
DPPIV activates and induces proliferation of human vascular smooth muscle cells, and this effect can be blocked using an inhibitor of the protease activated cell-surface receptor (PAR2), as well as a PAR2 siRNA. 14, 15 Protease-activated receptors (PARs) are a four-member family of G protein coupled receptors. 16 PAR2 is activated by proteolytic cleavage of an extracellular domain, 17 allowing a portion of the extracellular domain to bind to the receptor and activate it. 16 Small molecules such as AC55541, 18 and peptides that mimic the released extracellular domain, can be used as PAR2 agonists. 17, 19 PAR2 is expressed on neutrophils, 20 and in PAR2 knockout mice, depending on the tissue and insult used, lack of PAR2 can lead to more or less inflammation. 21 Other proteases also activate PAR2. Mast cells degranulate in response to external stimuli 22 to release factors such as the protease tryptase. [22] [23] [24] In addition to proteolysis of cell debris, tryptase also signals both monocytes and neutrophils through PAR2. 17, 22, [25] [26] [27] [28] Tryptase stimulates neutrophils to upregulate cell adhesion molecules, secrete proteins and cytokines such as lactoferrin and IL-8, and modulate neutrophil migration. 21, 29 Trypsin similarly activates PAR2 to induce inflammation. 21 In addition to PAR2, PARs such as PAR1 are present on neutrophils. 30 PAR1 is relatively insensitive to tryptase and trypsin, but is sensitive to the protease thrombin. 17, 25 There are several diseases that involve an excess number of neutrophils in a tissue, and where a neutrophil chemorepellent could be useful to decrease this localized accumulation of neutrophils. For instance, acute respiratory distress syndrome (ARDS) involves damage to the lungs recruiting neutrophils, neutrophils entering the lungs, activating and causing more lung damage, resulting in further recruitment of neutrophils in a vicious cycle that leads to the death of ∼40% of the ∼200,000 cases of ARDS in the United States. [31] [32] [33] [34] ARDS can be approximately modeled in mice by oropharyngeal aspiration into the lungs of damage-inducing agents such as bleomycin or bacterial LPS.
We previously observed that aspiration of the neutrophil chemorepellent DPPIV acts as a therapeutic in a mouse model of ARDS. 10 Since DPPIV is a peptidase that cleaves many proteins, 35 finding a more inert neutrophil chemorepellent would be more useful as a potential therapeutic. In this report, we show that PAR2 but not PAR1 agonists induce neutrophil chemorepulsion, that DPPIV and PAR2 agonists require PAR2 to induce this chemorepulsion, and that aspiration of low doses of PAR2 agonists are therapeutic in a mouse model of ARDS.
MATERIALS AND METHODS

Cell isolation and culture
Human blood was collected from volunteers who gave written consent and with specific approval from the Texas A&M University human subjects Institutional Review Board. All blood samples were deidentified prior to analysis. Peripheral blood neutrophils were isolated as previously described. 10 Neutrophils were isolated from the bone marrow of 6-to 10-week-old C57BL/6 and Par2 −/− (F2rl1; stock # 004993) mice (The Jackson Laboratory, Bar Harbor, ME, USA) as previously described. 36 All mouse experiments were performed in accordance with guidelines published by the National Institutes of Health, and the protocol was approved by the Texas A&M University Animal Use and Care Committee. Mouse genomic DNA was isolated from tail snips as described previously. 37 C57BL/6 and PAR2 −/− genotypes were vali- 
Proteases, PAR agonists, and PAR inhibitors
The PAR-1 inhibitor vorapaxar (Axon Medchem, Reston, VA, USA), PAR-1 agonist SFLLRN-NH2 (American Peptide Company, Sunnyvale, CA, USA), PAR2 agonists 2f-LIGRL-NH2 (EMD Millipore, Billerica, MD, USA), SLIGKV-NH2 (Tocris, Minneapolis, MN, USA), AC55541 (Tocris), TPCK-treated bovine trypsin (10,000 N -benzoyl-L-arginine ethyl ester units/mg, Sigma, St Louis, MO, USA), and human thrombin (1000 NIH units/mg; Sigma) were resuspended following the manufacturer's instructions. Tryptase purified from human mast cells (70 units/mg, Fitzgerald, Acton, MA, USA) mixed with 15 kDa heparin from porcine stomach (Sigma) in a 1:10 molar ratio of tryptase to heparin immediately after thawing, 38 and PAR2 inhibitor ENMD-1068 (50 g/ml; Enzo Life Sciences, Farmingdale, NY, USA) were used as previously described. 39 Tosyl-L-lysyl-chloromethane hydrochloride (TLCK; Sigma), an irreversible inhibitor of trypsin and trypsin-like serine proteases, was used at 10 nM, and the PAR-1 inhibitor vorapaxar was used at 25 g/ ml, both in RPMI/2% BSA.
Insall chamber assays
Insall chamber (a kind gift of Robert Insall, Beatson Institute for Cancer Research, Glasgow, UK) assays were used to determine the effect of compounds on PBMC and neutrophils in a chemotactic gradient, as previously described 5, 10 (Supplementary Figure 2) . PAR-1 agonist SFLLRN-NH2 and PAR2 agonists 2f-LIGRL-NH2, and SLIGKV-NH2 were added to one side of the Insall chamber at 50 ng/ml, AC55541 was added at 65 ng/ml, and trypsin, tryptase, and thrombin were added at 10 ng/ml. These concentrations were based on the concentrations of PAR2 agonists and proteases that we previously observed to potentiate human fibrocyte differentiation. 39 fMLP (Sigma) was used at 1 nM. Recombinant human DPPIV (Enzo Life Sciences, Farmingdale, NY, USA) was added at 2 nM, as previously described. 10 At least 10 neutrophils per experiment were tracked for 38 min. For each donor, neutrophils were tracked in a no-gradient control. Neutrophils were never used past 5 h from the end of the isolation step. We used two Insall chamber/ microscope/ camera setups in parallel, allowing six to eight experimental conditions to be measured per set of donor neutrophils. The results are expressed as the mean ± SEM of the movement of neutrophils from three or more different donors. We never used the same donor twice for a given experiment.
Neutrophil adhesion and survival
A total of 50 ng/ml 2f-LIGRL-NH2, 50 ng/ml SLIGKV-NH2, 130 ng/ml AC55541, 10 ng/ml trypsin, or 10 ng/ml tryptase were used to assess neutrophil survival, as previously described; 10,40 10 ng/ml TNF-(BioLegend, San Diego, CA, USA) was used as a positive control. The same concentrations of compounds were used to test neutrophil adhesion to fibronectin as previously described. 40, 41 After washing, neu- 
Immunohistochemistry of BAL and lung sections
Immunohistochemistry of BAL and lung sections was performed as previously described. 10, 41, 43 Cells and lung sections were stained with antibodies at 5 g/ml for CD11b (BioLegend), CD11c (BioLegend), Ly6g
(BD Biosciences, San Jose, CA), and CD45 (BioLegend), as previously described. 10,41,43
Statistical analysis
Data were analyzed by ANOVA (with Dunnett's posttest) or t test when appropriate using Prism software (GraphPad, San Diego, CA, USA). Statistical significance was defined as P < 0.05. Power analysis was done with StatMate (GraphPad).
RESULTS
DPPIV and PAR2 agonists act as neutrophil chemorepellents
We previously observed that DPPIV is a chemorepellent for human and mouse neutrophils. 10 Since PAR receptors are present on neutrophils, 28 Figure 3) . Gradients of the PAR1 agonist SFLLRN-NH2 or thrombin, which activates PAR1, 17, 25 did not significantly alter neutrophil FMI compared to a no gradient control ( Figure 1A) . Gradients of the PAR2 agonists 2f-LIGRL-amide, SLIGKV-NH2, or AC55541 induced chemorepulsion at concentrations that we had previously shown to potentiate fibrocyte differentiation 39, 44 ( Figure 1B) . The AC55541 was dissolved in DMSO before being diluted in culture medium, and an identical concentration of DMSO in culture medium did not cause chemorepulsion ( Figure 1B) . Together, these results indicate that a gradient of PAR2 but not PAR1 agonists causes neutrophils to move away from the source of the agonist. simply by increasing directness, that the protease inhibitor TLCK and the PAR2 inhibitor ENMD-1068 were not inhibiting chemorepulsion simply by inhibiting cell speed, and that PAR1 may affect cell speed.
PAR2 agonists do not increase neutrophil death
As migration is a combination of adhesion and motility, 46 SLIGKV-NH2, and AC55541 induce neutrophil chemorepulsion without having a major effect on neutrophil adhesion to fibronectin, and that they do not increase neutrophil death.
PAR2 is required for chemorepulsion of mouse neutrophils by PAR2 agonists
To test the hypothesis that PAR2 agonists require PAR2 to induce neutrophil chemorepulsion, we examined the movement of neutrophils from Par2 −/− mice. The original Par2 −/− mice were backcrossed to a C57BL/6 background at Jackson Laboratories, so we used C57BL/6
as the Par2 +/+ control. In the absence of a gradient, C57BL/6 and Par2 −/− neutrophils had no significant differences in FMI ( Figure 3A and Supplementary Figure The chemorepulsion from PAR2 agonists was observed for both male and female C57BL/6 mice, although DPPIV and AC55541 had a stronger effect on male compared to female mice. In the absence of a gradient, neutrophils from C57BL/6 female mice moved 31 ± 5% more directly than those isolated from C57BL/6 male mice, while in a fMLP gradient, the female neutrophils moved 21 ± 8% less directly than male neutrophils ( Figure 3E ). Female neutrophils moved more slowly than male neutrophils in gradients of AC55541 (23 ± 6% reduction), SLIGKV (25 ± 10% reduction), and fMLP (42 ± 6% reduction) ( Figure 3F ). For Par2 −/− mice, compared to male neutrophils, female neutrophils had a stronger attraction to fMLP, less directness in an AC55541 gradient (33 ± 9% reduction), faster speed in DPPIV (57 ± 9% increase) and fMLP (26 ± 8% increase), and slower speed in AC55541 (23 ± 9% reduction) ( Figure 3G-H) . Together, these results indicate that for both male and female mice, PAR2 is necessary for the chemorepulsion caused by PAR2 agonists. 
DISCUSSION
We previously found that DPPIV is a neutrophil chemorepellent. 10, 11 In this report, we show that the PAR2 agonists trypsin and tryptase, and three small-molecule PAR2 agonists, also act as chemorepellents for human neutrophils. The chemorepulsion does not appear to be due to a general activation of PARs, since PAR1 agonists do not appear to act as neutrophil chemorepellents and a PAR1 inhibitor was unable to inhibit chemorepulsion from trypsin. Three observations support the idea that PAR2 activation mediates the chemorepulsion. First, PAR2 activation by a protease requires the protease activity, 52 and the trypsin-specific protease inhibitor TLCK blocked the ability of trypsin and tryptase to induce chemorepulsion. Second, the PAR2 inhibitor ENMD-1068 blocked the ability of DPPIV, trypsin, and tryptase to induce chemorepulsion. Third, neutrophils from both male and female mice lacking PAR2 were insensitive to DPPIV and PAR2
agonist-induced chemorepulsion.
The chemorepellent AprA increased the directness of Dictyostelium cells, [5] [6] [7] 9 while DPPIV 10,11 and the PAR2 agonists induced chemorepulsion without increasing directness. This suggests a difference in the chemorepulsion mechanisms used by AprA compared to the DPPIV and PAR2 agonists. AprA did not affect cell speed, 5 and DPPIV and trypsin also did not affect speed, although tryptase and two of the three small-molecule PAR2 agonists increased cell speed. A common feature of the chemorepulsion induced by DPPIV and the PAR2 agonists thus appears to be an effect on the direction of cell movement without a significant increase in the directness of cell movement.
This type of chemotaxis is different from chemoattraction, where the chemoattractant tends to increase directness and speed. 53, 54 Other workers found that coaspiration of 0.5 mg of the PAR2 agonist SLIGRL along with LPS reduces LPS-increased neutrophil numbers in the BAL fluid of mice. 55 Depending on the model, disruption of Par2 can result in more or less inflammation, [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] suggesting that PAR2-mediated chemorepulsion might drive neutrophils into a region of inflammation in some circumstances, and drive neutrophils out in other circumstances. In this report, we found that aspiration of ∼2.5 ng of similar PAR2 agonists starting 24 h after the LPS insult also reduces the numbers of neutrophils in the both the BAL fluid as well as the post-BAL lung tissue in this model of ARDS. Our work thus extends the previous studies, suggesting that PAR2 agonists could be used therapeutically in addition to prophylactically, that the PAR2 agonists decrease neutrophils in the post-BAL tissue as well as the BAL, and that considerably lower doses of PAR2 agonists are effective. We also observed that aspiration of PAR2 agonists decrease LPS-increased CD11c-positive cell numbers in the post-BAL lung tissue, suggesting that aspirated PAR2 agonists decrease LPS-induced lung inflammation.
The observation that PAR2 agonists do not appear to decrease neutrophil viability suggests that the aspirated PAR2 agonist effects on decreasing lung neutrophil numbers in the mouse ARDS model were not due to PAR2-induced neutrophil cell death. In ARDS, chemoattractants appear to recruit neutrophils to the lungs, 34, 66 and in gradient chambers, some PAR2 agonists blocked the ability of the chemoattractant fMLP to recruit neutrophils. This then suggests that in the mouse ARDS model, the aspirated PAR2 agonists may have decreased LPS-increased lung neutrophil numbers either by inhibiting neutrophil recruitment to the lungs, or by actively inducing neutrophil chemorepulsion out of the lungs.
Of the 5 PAR2 agonists examined, only SLIGKV decreased neutrophil adhesion. We previously observed that the plasma protein serum amyloid P (SAP) decreases neutrophil adhesion to a variety of surfaces, and that intraperitoneal SAP injections in a mouse model of ARDS starting at 24 h after the insult decreases neutrophil numbers in the lungs. 40, 41 These observations suggest that aspiration of PAR2
agonists and injections of SAP might decrease lung neutrophil numbers in a mouse model of ARDS using different mechanisms. This in turn suggests that PAR2 agonists activating the PAR2-mediated chemorepulsion mechanism, and SAP decreasing the ability of neutrophils to strongly adhere to lung tissue, might act synergistically as potential therapeutics for ARDS.
